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A large amount of data supports a role for oxidized
low density lipoprotein (oxLDL) in atherosclerotic lesion
formation, while inappropriate platelet aggregation is an
important factor in advanced lesion formation. For this
reason, we investigated the effects of dietary vitamin E
supplementation, an antioxidant, on platelet aggregation
and oxidation of LDL in hypercholesterolemic rats, a
generally accepted model of atherogenesis. Rats received
normal chow (N) or chow containing 5% cholesterol (C) or
chow containing 5% cholesterol plus vitamin E. All rats
were maintained on the appropriate diet for a minimum of
eight weeks. In both the C and E groups, plasma levels of
total cholesterol and LDL cholesterol were significantly
greater than in the N group (p<0.0001). Triglyceride
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levels in the E group were significantly greater than in
the N group (p<0.05), while HDL cholesterol levels were
not significantly different between the three groups.
Platelet aggregation was not significantly different
between the hypercholesterolemic groups in response to
either 0.5 mM arachidonic acid or 5 µM adenosine
diphosphate. In both groups of rats whose diets were
supplemented with cholesterol, the LDL ultracentrifugation fraction of plasma contained TEARS
(thiobarbituric acid-reactive substances), which are
indicative of oxidation. Vitamin E supplementation to the
cholesterol diet significantly reduced TEARS in the LDL
samples by 38% (p<0.02). These results provide evidence
that vitamin E supplementation could be beneficial in
reducing atherosclerotic disease.
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INTRODUCTION

Cardiovascular disease is the leading cause of death
in the United States. In 1992, the latest year for which
data are available, the death rate for all causes was
2,177,000. Of this number, ischemic heart disease
accounted for 480,200 deaths, cerebrovascular disease for
143,600 deaths, and atherosclerosis for 16,100 deaths
(U.S. Bureau of the Census, 1994). Thus, 29% of all
reported deaths were a direct result of atherosclerotic
processes.
Evidence indicates that oxidation of low density
lipoprotein (LDL) is a significant event in the
atherosclerotic process. The main purpose of this study
was to explore the effects of a dietary antioxidant on
the oxidation of LDL and on the biological consequences
produced by oxidized LDL.
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Hypotheses of Atherosclerosis

The Response-to-Injury Hypothesis

In 1976, Ross and Glomset proposed the first widely
accepted theory of the events which lead to atherosclerotic disease. The Response-to-Injury Hypothesis came
out of the work from their laboratory as well as the
earlier works of many others. They proposed that
endothelial injury, especially focal desquamation, was
the initiating event in atherosclerosis. This injury
could occur via such factors as hyperlipidemia, hormone
dysfunction, or mechanical stress due to hypertension.

.

. desquamation' would expose subendothelial connective
This
tissue to platelets and other blood components. Platelets
would then adhere to collagen, aggregate, and release the
contents of their granules. This infiltration of platelet
factors, along with lipoproteins and possibly other
substances, would lead to focal smooth muscle cell (SMC)
proliferation; the formation of increased extracellular
matrix (ECM) components, ie. connective tissue; and the
deposition of lipid in the ECM and in SMC. If the source
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of this injury was removed, the lesion would regress.
However, if the causative factors were constantly
present, such as would be found in hypercholesterolemia,
these events would continue unabated. This would
eventually lead to atherosclerotic lesions.
In this hypothesis, it was felt that the subendothelium needed to be exposed for lesion initiation,
and that SMC were the predominant cell type in early
lesions. During the next decade, however, work by several
investigators shed much new light on the process of
lesion formation and the contents of the lesions
themselves.
Fatty streaks, which were found to occur early in
life at anatomical sites where fibrous plaques typically
develop, were shown to consist of lipid-laden macrophages
with underlying lipid-laden SMC (Stary, 1983).
Furthermore, several animal models of hypercholesterolemia demonstrated that one of the earliest
cellular interactions to occur was the attachment of
monocytes to the endothelium (Faggiotto et al., 1984b;
Joris et al., 1983; Silkworth et al., 1975; Gerrity,
1981a). It was shown, both in monkeys (Faggiotto et al.,
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1984b) and rats (Joris et al., 1983), that monocytes
gathered in clusters on the endothelium, migrated
subendothelially, accumulated lipid, took on the
appearance of foam cells, and finally led to the
development of the fatty streak. Although monocytes had
been shown to adhere preferentially to injured
endothelium in culture (DiCorleto et al., 1985), both
studies showed that these events occurred in the presence
of an intact endothelium. The laboratory of Joris also
found that platelet involvement was minimal at this
stage. In both animal models, as lesion development
progressed there was migration of monocytes, which
differentiated into macrophages; lipid-filled SMC
appeared, leading to streak enlargement and raised
plaques; platelet involvement increased; and advanced SMC
proliferative lesions appeared which contained a fibrous
cap of SMC and connective tissue, with underlying cells,
necrotic foam cells, extracellular lipids, collagen, and
calcification. This picture of fibrous plaque composition
was also demonstrated in humans (Ross et al., 1984). In
the study of Faggiotto and Ross (1984), the increased
platelet adherence and aggregation occurred only after
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endothelial cells separated and retracted over fatty
streaks at branch points. This led to mural thrombus
formation. Also supporting the role of monocytes was the
discovery that Interleukin-! (IL-1), produced by both
macrophages and endothelial cells (EC), induced increased
adherence of monocytes to the endothelium (Bevilacqua et
al., 1985) .

Much new evidence also emerged about the
endothelium. It was shown to produce vasoactive agents
(Moncada et al., 1977), growth factors (DiCorleto and
Bowen-Pope, 1983), and growth inhibitors (Castellot et
al., 1982). Individual EC were found to detach with rapid
replacement, leading to non-denuding injury (Reidy and
Schwartz, 1983; Reidy and Schwartz, 1984); and it was
discovered EC bound low density lipoprotein (LDL) with a
specific, high-affinity receptor, and modified and
transcytosed it (Steinberg, 1983).
Brown and Goldstein showed that cells have specific
LDL receptors, and that LDL self-regulation occurs by
controlling the number of receptors expressed, promoting
the intracellular storage of cholesterol, and limiting
the activity of HMG-CoA Reductase, the rate-limiting
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enzyme in cholesterol biosynthesis (1984).

It was also

shown that LDL incubated in the presence of macrophages
became oxidized, and that this LDL was cytotoxic to
fibroblasts (Cathcart et al., 1985). Finally, Jackson and
Gotto proposed that LDL may alter the cholesterol to
phospholipid ratio of EC membranes, leading to increased
membrane viscosity, decreased endothelial malleability,
and possible EC retraction (Jackson and Gotto, 1976).
New information concerning platelets also was
discovered. Platelets contain platelet-derived growth
factor (PDGF), which was shown to be mitogenic for SMC
and a chemoattractant for both SMC and monocytes (Deuel
et al., 1982; Grotendorst et al., 1982; Ross et al.,
1974). It was also shown to bind with high-affinity to
SMC but not to EC (Bowen-Pope and Ross, 1982). Platelets
also contain platelet factor 4 (PF4), which is released
during the release action and was shown to be chemotactic
for monocytes (Deuel et al., 1981). Finally, it was
demonstrated that the extent of endothelial injury
correlates linearly with the amount of platelet
accumulation (Reidy et al., 1983); and that intimal
proliferative lesions will not form in cases of
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endothelial denudation when platelets are absent
(Friedman et al., 1977; Moore et al., 1976).
From this and other evidence, Ross (1986) made
several general conclusions. He felt that monocyte
involvement precedes SMC accumulation in fatty streak
formation; that monocytes are the predominant cell type
in fatty streaks, while SMC are predominant in fibrous
plaques; that macrophages secrete growth factors for SMC
and EC; that macrophages can injure EC by forming toxic
substances and by oxidizing LDL; that EC normally inhibit
platelet release by producing vasoactive agents and by
their nonthrombogenic surface, and that platelet
adherence to modified EC may not be a common event; that
platelet interaction with the subendothelium leads to the
release of their granule contents; and that SMC can
respond to a variety of chemotactic factors. This led him
to conclude that "it is probably not necessary in many
cases for endothelial disjunction, retraction, or
subendothelial exposure to occur for atherosclerosis to
develop", and to propose the Revised Response-to-Injury
Hypothesis.
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The Revised Response-to-Injury Hypothesis

This hypothesis, like the earlier one, is based on
endothelial injury. However, Ross recognized that
"injury" need not mean denudation, but could include
events which precipitate biological changes in EC. He
proposed both a short path and a long path to fibrous
plaque formation. In the long path, injury may lead to
growth factor secretion by EC. Monocytes then attach to
the endothelium and also secrete growth factors. These
monocytes migrate to the subendothelium, continue to
release growth factors such as PDGF, and lead to fattystreak formation. Fibrous plaque formation then occurs
via one of two paths: 1) the release of growth factors
from macrophages and EC may lead to direct conversion, or
2) macrophages may stimulate or injure the overlying
endothelium, leading to EC loss, platelet attachment,
additional growth factor release, and eventual conversion
to fibrous plaques. In the short path, EC may be injured
yet remain intact, leading to increased EC turnover;
increased formation of growth factors by EC; and intimal
SMC migration with concomitant PDGF production. This
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would presumably lead to fibrous plaque formation.
While this hypothesis recognized the newly
discovered role of monocytes, it still did not place much
emphasis on the role of LDL in lesion development. It had
been known for several years that lesion cholesterol
originated primarily from plasma lipoproteins; and
epidemiological studies had linked increased levels of
plasma LDL and cholesterol with accelerated atherogenesis
and increased mortality from coronary heart disease
(Keys, 1970; Steinberg, 1983). It had also been
demonstrated that most foam cells arise from plasma
monocytes (Aqel et al., 1984; Bylock and Gerrity, 1988;
Faggiotto et al., 1984). But how did these cells
accumulate enough lipid to become foam cells? As
mentioned earlier, Brown and Goldstein had shown that the
uptake of LDL led to the down-regulation of the number of
LDL receptors expressed, and thus to a decrease in LDL
uptake. It had also been discovered that foam cells occur
in rabbits and humans deficient in LDL receptors (Buja et
al., 1983; Rosenfeld et al., 1987); and that neither
monocytes nor macrophages could be converted to foam
cells when incubated with high concentrations of LDL
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(Goldstein et al., 1979). Thus, a receptor-independent
pathway of LDL uptake seemed to be involved.
Part of the answer lay in the discovery of a
receptor on macrophages which mediated the uptake and
degradation of LDL which had been chemically modified by
acetylation (Goldstein et al., 1979). This receptor took
up concentrations of acetyl-LDL which were 20 times the
amount taken up of native LDL (nLDL), yet this receptor
did not bind nLDL. The result of this uptake was the
formation of foam cells. This receptor was dubbed the
"scavenger" receptor, and was subsequently found on EC.
However, acetyl-LDL had never been demonstrated in vivo,
so foam cell formation remained in part a mystery.
This mystery was solved with the discovery that
incubation of nLDL with SMC or EC led to a three- to tenfold increase in it's uptake by macrophages, and that
this uptake was primarily via the scavenger receptor
(Heinecke et al., 1984; Henriksen et al., 1983; Morel et
al., 1984). It was later shown that monocytes and
macrophages themselves could induce similar changes to
nLDL (Cathcart et al., 1985; Parthasarathy, 1986a). These
changes, producing a product commonly referred to as
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oxidized-LDL (oxLDL), are numerous. The initial step is
always the peroxidation of polyunsaturated fatty acids
(PUFA) found in the lipid portion of LDL. This has been
shown to be totally inhibited by the presence of
antioxidants (Morel et al., 1984; Steinbrecher et al.,
1984) or plasma. These modifications have also been shown
to be absolutely dependent on the presence of small
amounts of iron or copper, and perhaps on a cellular
lipoxygenase activity (Parthasarathy et al., 1989;
Sparrow et al., 1988). Other changes include an increase
in the negative charge of the particle; the oxidation of
cholesterol present in the LDL; the conversion of
lecithin to lysolecithin via a phospholipase A2 (PLA2 )
activity intrinsic to LDL (Parthasarathy et al., 1985);
the propagation of fatty acid fragmentation by the
modified PUFA, and the attachment of these fragments to
the apoprotein-Bl00 (apoB) present in LDL (Fong LG et
al., 1987); and the possible fragmentation of apoB (Fong
LG et al., 1987). The modified apoB was discovered to be
the part of the molecule recognized by the macrophage
scavenger receptor (Parthasarathy et al., 1987). Later
studies showed that high concentrations of iron or copper
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alone could mimic these results (Steinbrecher et al.,
1984).
Having discovered an in vitro form of LDL that could
induce foam cell formation, what was the evidence that
this process occurred in vivo? Monoclonal antibodies
(mAb) to oxLDL had been produced and detected material in

lesions but not in lesion-free areas of arteries from
Watanabe heritable hyperlipidemic (WHHL) rabbits. These
mAb also recognized LDL isolated from these lesions.

These investigators also discovered auto-antibodies to
oxLDL in both rabbit and human sera (Palinski et al.,
1989). Yet the isolation of oxLDL from atherosclerotic
lesions did not satisfactorily provide evidence for a
causative role of oxLDL in lesion formation. This
evidence came in part from an experiment in the
laboratory of Carew (Carew et al., 1987), which used WHHL
rabbits. These rabbits are genetically bred to be LDLreceptor deficient, yet still develop lesions when fed
high cholesterol diets. When treated with the powerful
antioxidant probucol, the rate of fatty streak
development decreased significantly. More importantly,
the uptake and degradation of LDL by lesion macrophages
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decreased by 50%. Probucol, which is transported in the
LDL particle, had also been shown to prevent oxidative
modifications of LDL and the resultant increase in
macrophage degradation in vitro; and probucol
significantly increased the ex vivo resistance to
oxidation of LDL in humans (Parthasarathy, 1986b).
Additional evidence for a role of LDL in atherogenesis came in two areas. The first involved the role of
monocyte recruitment and retainment. In addition to
monocyte chemoattractants produced by EC (Quinn et al.,
1987), SMC (Mazzone et al., 1983; Valente et al., 1988),
and macrophages (Mazzone et al., 1983), it was shown that
oxLDL, directly and by itself, was chemotactic for human
monocytes (Quinn et al., 1987). Additionally, oxLDL was
shown to inhibit macrophage motility (Quinn et al.,
1985), implying a role in keeping macrophages and foam
cells from leaving the lesion. The second area of
involvement was that of cytotoxicity. oxLDL was shown to
be highly cytotoxic to fibroblasts (Morel et al., 1983;
Morel et al., 1984), SMC, and EC (Hessler et al., 1979;
Morel et al., 1984). As mentioned earlier, Ross and
Glomset had recognized the importance of endothelial
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injury in atherogenesis. Although denudation does not
occur before fatty streak formation (Davies et al.,
1976), EC loss does occur over fatty streaks (Faggiotto
et al., 1984; Gerrity, 1981b). The cytotoxicity of oxLDL
could lead to EC changes which would promote monocyte
recruitment and endothelial denudation.
All of this evidence for the involvement of LDL in
atherogenesis led Daniel Steinberg et al. (1989) to
propose a new hypothesis concerning the initiation of
fatty streak formation.

The Lipid Infiltration Hypothesis

In 1989 several investigators who contributed many
of the discoveries noted above came together to propose
the lipid infiltration hypothesis as a means of
explaining fatty streak formation. In it they hypothesize
that increased plasma LDL levels lead to increased
intimal LDL levels. Here, a basal rate of LDL oxidation
by EC, SMC, and macrophages leads to the formation of
oxLDL. This oxLDL is chemotactic for monocytes, which
migrate subendothelially and differentiate into
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macrophages, whose motility is inhibited by the oxLDL.
The macrophages then further modify intimal LDL producing
additional oxLDL and increasing the effects of oxLDL.
Macrophages also uptake oxLDL via the scavenger receptor,
resulting in foam cell formation. Meanwhile,
extracellular oxLDL has two additional effects. It is
cytotoxic, and can lead to EC injury; and it is
immunogenic, leading to the formation of immune complexes
which are taken up by macrophages via the F receptor
0

(Brown and Goldstein, 1983).
This hypothesis was not proposed to be mutually
exclusive of the Response-to-Injury hypothesis. On the
contrary, it's authors felt that the cytotoxicity of
oxLDL could provide the EC injury which was important in
the earlier hypothesis, thus integrating the two
hypotheses.
While it explained a key role of LDL in atherogenesis, it did not explain why or how LDL accumulated in
the arterial intima. The artery wall is known to be
continuously permeated by lipoproteins (Lp), including
LDL (Vasile et al. 1983), but most of these exit via the
lymphatic system. However, in the presence of hyper-
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cholesterolemia LDL is taken up and degraded by the
endothelium. This massive influx of modified LDL is
concurrent with alterations in the ECM which lead to LDL
trapping (Simionescu et al., 1986). It has been shown
that when complexed with glycosaminoglycans or
chondroitin sulfate-proteoglycan, components of the ECM,
LDL uptake by macrophages is considerably increased
(Camejo et al., 1991). This implies a role for ECM
trapping, and suggests that this may be a local defense
reaction, as monocyte migration and differentiation
subsequently occur. It is assumed that the modifications
to LDL by EC prime it for further oxidation in the intima
(Witztum and Steinberg, 1991).
So how do lipoproteins get transported across the
endothelium? There may not be one specific answer. It is
known that a small amount of LDL is endocytosed by EC.
However, it was found that during hyperlipidemia, most Lp
are transcytosed in a receptor-independent manner via
plasmalemmal vesicles (Vasile et al., 1983). In an
experiment using rabbits, ~-VLDL (very low density
lipoprotein) was found to be transported in this manner
early in hypercholesterolemia (Simionescu et al., 1986).
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These vesicles then accumulated extracellularly in the
intima, and have been dubbed extracellular liposomes
(EL). At this stage, the endothelium was physically
intact and there was no monocyte or platelet involvement.
These EL have been observed in WHHL rabbits (Nievelstein
et al., 1991) and humans (Chao et al., 1990). They have
immunoreactive apoB fragments on their surface (Mora et
al., 1987), and can be obtained from LDL in vitro by
cholesteryl ester hydrolysis (Chao et al., 1992).
However, in rats it was shown that LDL can cross the
endothelium at intercellular junctions which are
transiently opened during EC turnover (Lin et al., 1989).
Hence there are at least three possible methods by which
intimal LDL accumulation can occur.
The transcytosed Lp undergo physicochemical
modification and reassembly of their components (Guyton
et al., 1991; Simionescu et al., 1986). These
extracellular products have been called modified and
reassembled lipoproteins (MRLp). In addition to EL, two
other forms have been found in prelesional stages, that
is before the involvement of monocytes. The first is self
aggregates, which have an increased uptake by macrophages
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(Khoo et al., 1988) but are more resistant to oxidation
than nLDL (Hermann and Gmeiner, 1992). These have been
demonstrated in rabbit arteries only two hours after a
bolus infusion of Lp (Nievelstein et al., 1991). The
second form is lipid droplets, which have also been
formed in vitro by the aggregation of LDL (Guyton et al.,
1991). In aortas collected from rabbits during the
prelesional stage (Mora et al., 1990), the crude MRLp
fraction had a 3-fold increase in oxidative products, and
also contained phospholipids, fragmented apoB, and
increased amounts of unesterified cholesterol. When
isolated separately, the EL fraction had only
phospholipids, unesterified cholesterol, and surprisingly
albumin at the EL core. This presence of albumin, a
powerful antioxidant, further attests to a local defense
reaction. Albumin has been shown to prevent LDL oxidation
and the formation of MRLp in cell-free systems (Dobrian
et al., 1993).
Once MRLp have collected beneath the endothelium,
they can induce constitutive changes in the overlying EC
in conjunction with the continuing hypercholesterolemia
(Simionescu and Simionescu, 1993). These changes can
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include impairment of the EC response to specific
stimuli; impairment of nitric oxide (NO) production, a
vasodilatory mediator, which can lead to an increased
risk of vasospasm; secretion of growth factors and
cytokines such as PDGF and IL-1, which is believed to
increase the adhesivity of EC for monocytes; production
of MCP-1 (monocyte chemotactic protein 1)

(Cushing et

al., 1990), which is chemotactic specifically for
monocytes and regulates EC adhesion molecules; secretion
of PAI-1 (plasminogen activator inhibitor 1) which can
lead to a decrease in the antithrombotic character of the
endothelium (Libby and Hansson, 1991); and increased EC
mitosis and possibly cell death, which can increase the
permeability of the endothelium to Lp. In advancing
lesions, EC may even become foam cells, leading to
endothelial denudation.
All of this evidence led Maya and Nicolae Simionescu
to propose in 1993 an expanded theory for the development
of atherosclerotic lesions.
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Theory of Prelesional Changes in the artery wall

In this unnamed theory, the researchers concentrated
on events occurring in the artery wall before the
involvement of monocytes. They proposed that increased
concentrations of plasma LDL creates a concentration
gradient across the endothelium, which leads to increased
endothelial transport of LDL, primarily by transcytosis.
These transported Lp are chemically modified, especially
by lipid peroxidation. The exact location of these
changes are still not known, and probably consist of more
than one mechanism. These Lp then associate in one of the
three forms mentioned earlier, that is self aggregates,
lipid droplets, or EL, which are trapped by the ECM. The
combination of MRLp on the abluminal side of the EC, and
hypercholesterolemia on the luminal side induces
constitutive changes in the EC without physical
alteration. The EC then produce chemoattractants and
monocyte adhesion molecules, following which monocytes
"roll" across the endothelium, bind the adhesion
molecules, and migrate through EC junctions to the
subendothelium under the influence of oxLDL. These
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monocytes then differentiate into macrophages, uptake and
degrade large amounts of the MRLp, and transform into
foam cells, now defining a fatty streak lesion. Growth
factors produced by local cells then stimulate SMC
migration and proliferation into the intima, leading to
an advanced lesion. Eventually, calcification, necrosis,
and thrombosis occur which leads to the advanced
obstructive fibrous plaque.
Simionescu and Simionescu (1993) concluded that it
is not feasible to determine exactly the events leading
to atherosclerosis in humans, and that a unified,
coherent hypothesis of atherogenesis is yet to come. They
felt that LDL oxidation begins as a protective mechanism
aimed at allowing it's uptake by macrophages, and that
the atherogenic process is a local defense reaction.
Unfortunately, this reaction rapidly leads to EC
dysfunction, and the eventual atherosclerotic plaque. A
summary of the events in atherogenesis based on current
knowledge and an integration of the above hypotheses is
presented in Tables 1 and 2.
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Table 1. Summary of Events in Early Atherosclerotic Lesion Formation.
Fatty Streak Formation
Stage Ia - Initiating Events
• Increased plasma [LDLJ create a concentration gradient across the endothelium.
• This leads to an increased intimal [LDLJ via three mechanisms:
- EC transcytose LDL in a R.,-independent manner yielding mmLDL/oxLDL.
- EC endocytose LDL via a specific R.,.
- LDL crosses at cell junctions during EC turnover.
• A basal rate ofLDL oxidation by EC, SMC, and MO exists
(possibly via free radicals).
• Increased intimal [LDL] lead to ECM trapping ofLDL and ECM-LDL complex
formation.
• Monocytes are recruited via three mechanisms:
- mmLDL induces EC production ofMCP-1 and IL-1.
- oxLDL is directly chemotactic for monocytes.
• Monocytes adhere to EC via pseudopodia then migrate to the subendothelium.
• Monocytes differentiate into MO.
• MO, via the scavenger R.,, have an increased uptake of:
-oxLDL.
- ECM-LDL complexes.
- glycosylated LDL (as in Diabetes).
• MO, via the F.,R, have an increased uptake of:
- LDL immune complexes.
• Lipid-laden MO become foam cells, leading to the characteristic fatty streak.
Stage lb - Concurrent events during and after monocyte and LDL accumulation
• MO, EC, and monocytes oxidize LDL.
•oxLDL:
- prevents MO migration (departure).
- is cytotoxic to SMC and EC.
- inhibits EC production of the vasodilators:
- PGI2, which also inhibits platelet aggregation.
-EDRF/NO.
• MO produce IL-1, a monocyte chemotactic factor.
Abbreviations used: EC - endothelial cells; R., - receptor; mmLDL - minimally modified LDL;
oxLDL - oxidized LDL; SMC - smooth muscle cells; MO - macrophages; ECM - extracellular
matrix; MCP-1-monocyte chemotactic protein-1; IL-1 - interleukin-1; F,R- receptor for
immunoglobulin; PGI, - prostacyclin; EDRF/NO - endothelium derived relaxing factor/nitric
oxide.
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Table 2. Summary of Events in Advanced Atherosclerotic Lesion Formation.
Stage II - Advanced Lesion Formation
• EC injwy from oxLDL leads to:
- increased EC turnover (also influenced by MO growth factors).
- focal desquamation by means of:
-EC death.
- EC retraction
- secretion of growth factors.
• Exposure of the subendothelium leads to:
- Platelet adherence to subendothelial collagen.
- Platelet aggregation and release of:
- PF4, a monocyte chemoattractant.
- TXA2, a promoter of aggregation.
- PDGF, a monocyte and SMC chemoattractant plus a factor for SMC
proliferation.
• Platelet aggregation leads to:
- mural thrombus formation.
- possible vessel occlusion.
• SMC proliferation leads to:
- additional oxidation ofLDL
- additional production of monocyte chemoattractants.
- additional production ofECM components.
- uptake of oxLDL by SMC leading to additional foam cells.
• oxLDL cytotoxicity leads to foam cell necrosis, giving an extracellular lipid core.
Stage III - Occlusive Thrombus Fonnation
• EC take up oxLDL leading to:
- additional foam cells.
- additional denudation.
• A fibrous cap of SMC and ECM occurs.
• Plaque rupture can occur, leading to an occlusive thrombus.
Abbreviations used: EC - endothelial cells; oxLDL - oxidized LDL; MO - macrophages; PF4 platelet factor 4; TXA2 - thromboxane A2; PDGF - platelet derived growth factor; SMC smooth muscle cells; ECM - extracellular matrix.
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Antioxidants

Since most research points to the oxidation of LDL
as a key event in the initiation of the atherosclerotic
lesion, it is only natural to ask what can be done to
prevent this from happening. Much research has been
devoted to the effects of antioxidants and their possible
role in the prevention of atherogenesis. While mention
will be made of some of the synthetic antioxidants in
use, the natural antioxidant vitamin E will be
concentrated upon. The effects of antioxidants on
platelet function will be discussed in a subsequent
section.
Vitamin E, or a-tocopherol, is the major lipidsoluble, chain-breaking (i.e. peroxyl radical-trapping)
antioxidant in human plasma. This is true in normal and
severe vitamin E-deficient states (Ingold et al., 1987).
It is also transported in the LDL particle, with an
average of six a-tocopherol molecules per LDL particle
(Esterbauer, 1992). It is thought to increase membrane
stability by decreasing permeability and interacting with
polyunsaturated phospholipids (PUPL)

24

(Diplock et al.,

1977; Maggio et al., 1977).
The in vitro antioxidant effects of vitamin E have
been found to be somewhat variable. Several studies have
found it to prevent the oxidation of LDL by EC, SMC,
monocytes, PMN (polymorphonuclear) cells, and iron
(Cathcart et al., 1985; Lindsey et al., 1985;
Steinbrecher et al., 1984). It was shown to prevent cu 2 +mediated oxidation at five but not 24 hours (Jialil et
al., 1990); and similar results were obtained for the
iron-mediated oxidation of PUPL when it was used in
physiological concentrations (Leung et al., 1981).
Finally, it was unable to prevent oxidation of LDL
induced by ultraviolet radiation (Negre-Salvayre et al.,
1991). However, a-quinone, a highly oxidized product of
vitamin E, has been shown to equally inhibit the
oxidation of LDL by SMC and iron (Lindsey et al., 1985).
This raises questions involving vitamin E as an
antioxidant, so the role of vitamin E needs further
investigation.
In addition to research on the role of vitamin E as
an antioxidant, work has also been conducted on a
possible role in the prevention of biological
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consequences such as cytotoxicity by previously oxidized
LDL. Again, the results have been variable. One report
found that it prevented the cytotoxicity of previously
oxidized LDL (Negre-Salvayre et al., 1991), while another
found that it did not prevent cytotoxicity, although it
did prevent the formation of cytotoxic LDL (Morel et al.,
1983). This lends further support to the concept that LDL
oxidation leads to cytotoxicity.
While the results of in vitro experiments have
differed, epidemiological studies conducted have been
remarkably in agreement. There has been shown to be a
significant inverse correlation between oral vitamin E
intake and plasma concentrations of vitamin E, and the
incidence of angina, coronary heart disease (CHD), and
mortality from CHD (Gey et al., 1991; Riemersma et al.,
1991; Rimm et al., 1993; Stampfer et al., 1993). This was
true for both males and females, even when adjusting for
several other risk factors.
Yet epidemiologic studies can not provide a causeand-effect relationship. There are too many unknown and
uncontrolled variables. For this reason, several studies
have been conducted on the effects of controlled vitamin

26

E supplementation in both animals and humans.
In rabbits fed a high cholesterol diet, vitamin E
completely inhibited the increase in LDL oxidation seen
in rabbits not given vitamin E (controls). It also
significantly inhibited the fall in prostacyclin (PGI 2 )
production seen in controls (Szczeklik et al., 1985).
PGI 2 is an endothelium-derived vasodilator, and it's
production is often decreased in atherosclerotic disease.
PGI 2 also inhibits platelet aggregation and release
(Aviram et al., 1985).
In rats, various levels of vitamin E supplementation
significantly reduced the amount of lipid peroxidation
products present in plasma (Lenz et al., 1991; Umegaki et
al., 1991), urine (Lee HS et al., 1992), and liver tissue
(Lee and Csallany, 1987) when compared to controls. In
the studies that measured oxidation of lipids in plasma,
LDL oxidation was not determined. As in rabbits, vitamin
E also attenuated the fall in PGI 2 production seen in
control rats (Karpen et al., 1981).
Several factors have been studied in humans
supplemented with vitamin E. It should be noted that a
wide range of dosages and lengths of supplementation have

27

been tested, and it is possible that these variances
could cause conflicting results. These variables will be
discussed in appropriate cases.
None of the studies showed a change in the levels of
plasma lipids (total cholesterol (TC), LDL, high density
lipoprotein (HDL), and triglycerides (TG))

(Dieber-

Rothender et al., 1991; Jialil and Grundy, 1992; Salonen
et al., 1991; Szczeklik et al., 1985). All of the studies
found that the supplement was absorbed, as plasma, LDL,
and platelets had significantly increased concentrations
of vitamin E (Belcher et al., 1993; Dieber-Rothender et
al., 1991; Jialil and Grundy, 1992; Kockmann et al.,
1988; Princen et al., 1992; Stampfer et al., 1988;
Szczeklik et al., 1985). These studies found that
supplementation significantly decreased the amount of
oxLDL present in plasma (Lake et al., 1977; Salonen et
al., 1991; Szczeklik et al., 1985). When subjected to ex

vivo oxidation using cu 2•, heme, or cell-mediated systems,
the rate of oxidation was found to be significantly
decreased (Jialil and Grundy, 1992; Princen et al.,
1992); while the resistance to oxidation was
significantly increased, by as much as 75% (Belcher et
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al., 1993; Dieber-Rothender et al., 1991; Jessup et al.,
1990; Mackness et al., 1993; Princen et al., 1992; Reaven
et al., 1993). Only one study found no correlation
between oxidative resistance and the concentration of
vitamin E in LDL (Jessup et al., 1990). One study looked
at the ex vivo cytotoxicity to EC by the supplemented
LDL, and found it to be significantly decreased (Belcher
et al., 1993). Finally, two studies found that, unlike in
animals, PGI 2 production was not altered (Fitzgerald and
Brash, 1982; Stampfer et al., 1988). However, both
studies were measuring plasma levels of PGI 2 , a paracrine
signal molecule.
Probucol is the most significant synthetic antioxidant for which studies have been conducted. It has
been shown to totally inhibit the in vitro oxidation of
LDL by several methods (Balla et al., 1991; McLean and
Hagaman, 1989; Parthasarathy, 1986b); to significantly
decrease intimal lipid accumulation and macrophage uptake
of LDL in rats (Shankar et al., 1989); and to
significantly increase the resistance of plasma LDL to
oxidation in rabbits (Kita et al., 1987) and humans
(Parthasarathy, 1986b).
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Antioxidants. Low Density Lipoprotein and Platelets

As discussed earlier, platelets have been shown to
play an important role in the formation of advanced
atherosclerotic lesions. They circulate in the blood in
an inactive state, unable to bind to normal endothelium.
However, platelets readily bind to injured endothelium,
as platelet stimulants such as collagen are exposed.
Platelets initially bind in a single layer, a process
known as adhesion. The platelets then release contents
stored in their granules which promote vasoconstriction
and assist in the process of aggregation, or the
formation of a platelet plug. One of the molecules
released is S-thromboglobulin (S-TG), which binds
specific receptors on EC and inhibits PGI 2 production
(Hope et al., 1979). It can be used to quantitate in vivo
platelet activation (Williams et al., 1985). Aggregation
is mediated by the binding of fibrinogen between
GPIIB/IIIA complexes on adjacent platelets, which are
exposed upon activation (Coller, 1986). Concurrently, the
blood coagulation cascade may be occurring. This leads to
the formation of a fibrin web around the platelet plug,
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giving a fibrin clot. While this process is intended to
control bleeding in a severed vessel, it's initiation by
endothelium injured by atherosclerotic processes leads to
the formation of a mural thrombus. This may eventually
lead to occlusion of the artery, with resulting ischemia
and possible tissue infarction distal to the site of the
occlusion.
Several platelet interactions occur in atherosclerosis which promote the formation of advanced
lesions. As discussed earlier, PDGF, which is released
during platelet activation, is a SMC mitogen and is
chemotactic for both SMC and monocytes. Thus, it's
release can increase monocyte involvement and induce SMC
proliferation into the intima. As SMC can form ECM (Burke
and Ross, 1979), this complicates the lesion and can
increase the uptake by macrophages of LDL which become
complexed with ECM components. PDGF has also been shown
to increase the number of LDL receptors on SMC, leading
to increased uptake and degradation of LDL (Chait et al.,
1980). This can lead to additional foam cell formation.
Platelets also interact with cholesterol, leading to
inappropriate responses. Platelets have a specific
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receptor for LDL (Aviram et al., 1981) which has been
shown to recognize nLDL and oxLDL with the same affinity
(Pedreno et al., 1994). This receptor has been shown to
be different from the LDL receptor on nucleated cells
(Pedreno et al., 1992), and may be a part of the
GPIIb/IIIa complex (Koller et al., 1989), although this
interpretation has been questioned (van Willigen et al.,
1994). LDL significantly increases platelet release of
~-TG (Aviram and Brook, 1984). This is one of the ways in
which LDL enhances aggregation. Nearly all studies have
shown that regardless of its state of oxidation, LDL
significantly increases in vitro aggregation in response
to ADP (Ardlie et al., 1989; Hassall et al., 1983; Naseem
et al., 1993; van Willigen et al., 1994), thrombin
(Ardlie et al., 1989; Aviram and Brook, 1983; Aviram et
al., 1985; Naseem et al., 1993; Shmulewitz et al., 1984),
and epinephrine (Ardlie et al., 1989; Hassall et al.,
1983). Oxidized LDL has even been shown to produce
aggregation in the absence of other agonists (Ardlie et
al., 1989; Naseem et al., 1993). Only one study showed a
decrease in platelet aggregation in the presence of LDL,
and this was only when using nLDL (Naseem et al., 1993).
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These proaggregatory effects were abolished when the LDL
binding protein was modified (Hassall et al., 1983;
Shmulewitz et al., 1984; van Willigen et al., 1994),
implying that LDL must bind to platelets before inducing
an effect. LDL may enhance aggregation by promoting an
increase in the binding of fibrinogen to platelets
(Naseem et al., 1993; van Willigen et al., 1994).
Similarly, ex vivo studies have shown that platelets from
both hypercholesterolemic humans (Carvalho et al., 1974;
Shattil et al., 1977) and rats (Winocour et al., 1989)
have significantly increased aggregation in response to
several stimuli. One study (Shattil et al., 1977) showed
that the cholesterol concentration of platelet membranes
was increased. Another study showed that LDL decreased
platelet membrane fluidity (Ardlie et al., 1989). These
findings seem to point to a possible role of changes in
membrane stability in aggregation.
Clearly, hypercholesterolemia and platelet aggregation and release are intertwined with atherogenesis.
Therefore, much research has been performed to determine
whether antioxidants can reduce platelet interactions
with atherosclerotic lesions.
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In several in vitro studies, vitamin E inhibited or
prevented platelet aggregation and release in response to
arachidonic acid (AA), ADP, epinephrine, thrombin, and
collagen (Agradi et al., 1981; Fong JSC, 1976; Kockmann
et al., 1988; Srivastava, 1986; Steiner and Anastasi,
1976; Steiner and Mower, 1982; White et al., i977). This

occurred in a dose-dependent manner with the release
reaction and AA-induced aggregation being especially
susceptible. However, a-quinone was shown to equally
inhibit aggregation (Mower and Steiner, 1982), suggesting
that vitamin E may act through a mechanism other than
it's antioxidant abilities.
In vivo studies with vitamin E have provided very

inconsistent results. In rats, platelet aggregation in
response to collagen and ADP decreased significantly in
the presence of vitamin E (Umegaki et al., 1991). In
humans, platelet aggregation studies have given mixed
results in regard to vitamin E. While most studies showed
a decrease in AA-induced aggregation (Fitzgerald and
Brash, 1982; Kockmann et al., 1988; Szczeklik et al.,
1985), studies were evenly split between a decrease and

no change in aggregation when using ADP (Fitzgerald and
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Brash, 1982; Lake et al., 1977; Salonen et al., 1991;
Stampfer et al., 1988; Steiner, 1983; Szczeklik et al.,
1985) and epinephrine (Lake et al., 1977; Steiner, 1983).
Dosages of vitamin E were comparable between the groups
with decreased aggregation and the groups showing no
change. The results for platelet adhesion, however, have
been more promising. Supplementation has demonstrated a
significant decrease in ex vivo platelet adhesion (Jandak
et al., 1988; Jandak et al., 1989; Steiner, 1983). The
decrease was inversely correlated with platelet membrane
vitamin E concentrations, and was accompanied by a
significant decrease in the number of extruded pseudopodia visible with scanning electron microscopy (Jandak
et al., 1989). This further supports a role for vitamin E
in membrane stabilization. Indeed, a separate study found
that platelet membrane fluidity decreased significantly
with supplementation (Steiner, 1991). Finally, plasma
levels of ~-TG were found to be significantly reduced
with supplementation, implying a decrease in in vivo
platelet activation (Salonen et al., 1991).
In our present study, we examined the effects of a
high cholesterol diet and vitamin E supplementation in
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rats on ex vivo platelet aggregation and the amounts of
lipid peroxidation products present in plasma. We
addressed two questions:

(1) Does vitamin E

supplementation alter ex vivo platelet aggregation
induced by arachidonic acid and adenosine diphosphate in
hypercholesterolemic rats?; and (2) Does vitamin E
supplementation alter plasma levels of oxLDL as measured
by thiobarbituric acid-reactive substances in
hypercholesterolemic rats?
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MATERIALS .AND METHODS

Materials

Thiobarbituric acid (TBA), Trichloroacetic acid
(TCA), Tetramethoxypropane (TMP), Ethylenediaminetetraacetate (EDTA), Potassium Bromide (KBr), and bovine
serum albumin (BSA) were obtained from Sigma Chemical
Company. Bio-tal anesthetic (Thiamylal Sodium) was from
Bio-Ceutic. Sterile normal saline was from Travenol.
Adenosine Diphosphate (ADP) and Arachidonic acid (AA)
reagents were obtained from Chrono-Log.
Chemicals for the determination of total cholesterol, HDL cholesterol, and triglycerides were obtained
from Sigma Diagnostics. All other chemicals used were
from Fisher Scientific.
Male rats (275 g to 299 g) were obtained from Harlan
Sprague Dawley. The animals were housed in the Lappin
Hall animal facility, with alternating 12 hour periods of
light and dark. Purina 5001 laboratory rodent diet with
0.02% cholesterol and 49 mg of vitamin E per kg of diet
was used as the

normal (N) diet. A preparation of the
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Purina 5001 diet with 5% cholesterol plus 1% sodium
taurocholate represented the cholesterol (C) diet. The
cholesterol preparation plus 300 mg of a-tocopherol
acetate per kg of diet comprised the cholesterol plus
vitamin E (E) diet. These two dietary preparations were
obtained from Bio-Serv. The use of 300 mg of a-tocopherol
was based on the prior work of Giani et al.

(1985), in

which supplementation of vitamin E to a diet containing
heated fat potentiated the antiaggregatory activity of
the arterial wall of rats, resulting in inhibition of
platelet aggregation.

Methods

The male Sprague-Dawley rats were divided into three
dietary groups, N, C, and E, containing 10, 10, and 11
rats respectively. All rats were fed a diet of normal
chow for two weeks. The C group was then switched to the
cholesterol chow, while the E group was switched to the
cholesterol chow supplemented with vitamin E. The N group
continued to receive the normal chow. All groups were
maintained on the appropriate diet for a minimum of eight

38

weeks. Food and water were supplied ad libitum.

Specimen Collection

Each rat was anesthetized by intraperitoneal
injections of 15 mg Bio-tal per 100 g body mass. All
blood was drawn using 3cc syringes with 22g one inch
needles. Blood for the platelet aggregation studies was
collected using 1 part of 3.4% trisodium citrate per 9
parts of blood. Blood for all remaining studies was
collected using 1 part of 10.0% EDTA (pH 7.4) per 9 parts
of blood.
The tail artery was used to collect as much blood as
possible, with 6.0 ml representing the maximum amount
obtained. The rat's abdominal cavity was then dissected,
and blood was collected from the inferior vena cava.
Appropriate samples were then transferred into a 12 ml
polycarbonate centrifuge tube. After all samples were
obtained, the animal was sacrificed with an overdose of
Bio-tal.
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Specimen Preparation

From the citrated blood, two aliquots of 0.5 ml each
were dispensed into cuvettes containing 0.5 ml of Tyrodes
solution and a stir bar. These samples were maintained at
37 °C for use in the platelet aggregation studies. From

the remaining sample, a hematocrit was determined using a
micro-hematocrit tube.
The EDTA blood was centrifuged in a Clay-Adams
analytical centrifuge for 5 minutes to obtain plasma. The
plasma was withdrawn and placed in a polypropylene tube,
from which 600 - 800 µl was removed and placed in a
separate tube for use in plasma lipid determinations. The
remaining plasma sample in the polypropylene tube was
used for LDL extraction. All the EDTA samples were stored
at 4 °c.

Platelet Aggregation studies

Aggregation, induced by ADP and AA,

was measured

using a Chrono-Log whole blood aggregometer in accordance
with procedures published by Chrono-Log Corporation
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(Galvez et al., 1986). The agonists ADP and AA were
prepared and kept wrapped in foil and on ice. To one of
the samples (0.5 ml citrated blood plus 0.5 ml Tyrode's
solution), 5 µl of 1 rnM ADP was added for a final
concentration of 5 µM, while to the second sample 10 µl
of 50 rnM AA was added for a final concentration of 0.5
rnM. Aggregation was measured for a period of 5 minutes.

Plasma Lipids Determination

Total cholesterol (TC) was determined using a
modification of the method of Allain et al.

(1974) Sigma

Diagnostics procedure No. 352. HDL cholesterol (HDL) was
determined using a modification of the method of Warnick
et al.

(1982) Sigma Diagnostics procedure No. 352-3.

Triglycerides (TG) were determined using a modification
of the method of McGowan et al. (1983) Sigma Diagnostics
procedure No. 339. Cholesterol calibrators and controls
from Sigma Diagnostics were also used. Spectrophotometric
readings were made with a Milton Roy model 1201 spectrophotometer using polystyrene cuvettes (Sarstedt).
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Isolation of LDL

LDL was isolated using density gradient ultracentrifugation (Puhl et al., 1994). The KBr solutions
were purged with N2 gas for 5 minutes before use. Beckman
polyallomer tubes (13.2 ml) were used for the samples.
Plasma was adjusted to a density of 1.22 using KBr. The
density layers were added to the tube from the bottom up,
starting with a solution of density (d) 1.005 (3.0ml).
Beneath this was added the 1.05d KBr (3.0ml), then the
1.08d KBr (3.0ml), and finally the 1.22d plasma sample
(2.0ml). The tube was then filled with the 1.005d
solution. The samples were then centrifuged in a Beckman
XL-90 ultracentrifuge using an SW28 rotor with SW28.l
buckets. The centrifugation was for 36 hours and 51
minutes at 28000 rpm and 10 °C. This gave excellent
separation of the various lipoproteins, with the LDL
being the yellow, second layer from the top of the tube.
The LDL was extracted using a syringe and needle,
filtered through a 0.2 µM filter, purged with N2 , and
stored in sterile 1.5ml polypropylene tubes at 4 °C.
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Determination of Plasma Lipid Peroxides

TEARS (thiobarbituric acid-reactive substances) were
determined using a modification of the methods of Yagi
(1976) and of Steinbrecher et al. (1984). The reaction
mixture contained 1.5 ml of 0.67% thiobarbituric acid,
1.5 ml of 20.0% trichloroacetic acid, and an aliquot of
LDL representing 25 µg of LDL. This aliquot was
determined by calculating the protein concentration from
the LDL total cholesterol content (Puhl et al., 1994).
The mixture was vortexed, and the solution heated for 30
minutes in a 100 °C water bath. The samples which
contained TEARS produced a pink color. The samples were
cooled 5 minutes before adding 3.0 ml of n-butanol and
vortexing. They were then

allowed to stand until

complete separation occurred. This resulted in the
samples turning a golden yellow. The top layer was placed
in cuvettes and fluorescence measured using a PerkinElmer model 650-l0S fluorescence spectrophotometer with
an excitation wavelength of 534 nm and an emission
wavelength of 551 nm. Standards of 0.05 nM, 0.1 nM, 0.2
nM, and 0.4 nM tetramethoxypropane, which yield
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malondialdehyde (MDA), were used. Results are expressed
as nanomoles of MDA equivalents.

Data Analysis
All statistics were performed using SAS and the GLM
procedure (an ANOVA procedure for unbalanced numbers of
samples). Differences between groups were determined
using the T (LSD), Scheffe, and SNK procedures.

44

RESULTS

Plasma Lipids

Total cholesterol and LDL cholesterol were
significantly increased in both diets supplemented with
5% cholesterol (p<0.0001), but the cholesterol without
vitamin E (C) and the cholesterol with vitamin E (E)
groups were not different from each other (Table 3,
Figures 1 and 4). Triglycerides were significantly higher
in the E group only in comparison with the group not
supplemented with cholesterol (N)

(p<0.05, Table 2 and

Figure 2). There was no diet-induced difference in HDL
cholesterol levels (Table 2 and Figure 3).

Platelet Aggregation

There were no significant differences between the C
and E group platelet aggregation responses to either 0.5
mM arachidonic acid (AA) or 5 uM ADP (Table 4, Figures 5

and 6).
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Plasma TBARS

Analysis of the LDL fractions revealed the presence
of TBARS in both groups of rats which received dietary
cholesterol. There was 38% less TBARS in the LDL fraction
from the hypercholesterolemic rats which received the
dietary supplement of vitamin E. This was statistically
significant (p<0.02, Figure 7).
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TABLE 3.
Assayed values of plasma lipids in the normal diet group (N),
cholesterol supplemented group (C), and cholesterol+ vitamin E
supplemented group (E).

Group

C

N

Total Cholesterol1
LDL

1

Triglycer ides 1
HDL1

50
6
33
38

±
±
±
±

8.0
2.9
10.6
6.8

191
135
54
51

±
±
±
±

E

44. 2•
34. 0•
26.8
21.2

175
109
57
51

±
±
±
±

54. 6"
42. 6'
20. 7b
19.8

1

- mg/dL (expressed as mean± standard deviation)
' - p<0.0001 vs. N
b - p<0.05 vs. N

TABLE 4.
Measurements of platelet aggregation induced by 5 µM ADP (adenosine
diphosphate) and 0.5 mM AA (arachidonic acid) in the normal diet
group (N), cholesterol supplemented group (C), and cholesterol+
vitamin E supplemented group (E).
Group
N

AA aggregation'
ADP aggregation1
1

-

7.02 ± 3.8
7.47 ± 3.5

C
8.61 ± 4.4
11.9 ± 7.1

impedance change (ohms) 5 minutes after agonist
addition (expressed as mean± standard deviation)
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E

6.22 ± 6.1
8.54 ± 4.3

N

C

E

Figure 1. Plasma total cholesterol (TC) levels in the normal
diet group (N), cholesterol supplemented group (C), and
cholesterol+ vitamin E supplemented group (E). Both c and E
are significantly greater than N (p<0.0001).

60

so

-

40

~

~

)30

~w
10
0
N

C

E

Figure 2. Plasma triglyceride (TG) levels in the normal diet
group (N), cholesterol supplemented group (Cl, and
cholesterol+ vitamin E supplemented group (El. Eis
significantly greater than N (p<0.05).
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Figure 3. Plasma HDL cholesterol levels in the normal diet
group (N), cholesterol supplemented group (C), and
cholesterol+ vitamin E supplemented group (E). There are no
significant differences.
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Figure 4. Plasma LDL cholesterol levels in the normal diet
group (N), cholesterol supplemented group (C), and
cholesterol+ vitamin E supplemented group (E). Both c and E
are significantly greater than N (p<0.0001).
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Figure 5. Comparison of arachidonic acid-induced platelet
aggregation for the normal diet group (N), cholesterol
supplemented group (C), and cholesterol+ vitamin E
supplemented group (E). There are no significant
differences.
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Figure 6. Comparison of ADP-induced platelet aggregation for
the normal diet group (N), cholesterol supplemented group
(C), and cholesterol+ vitamin E supplemented group (E).
There are no significant differences.
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E

C

Figure 7. oxidized LDL as measured by TEARS (thiobarbituric
acid-reactive substances) for the cholesterol supplemented
group (C) and the cholesterol+ vitamin E supplemented group
(E). Results for E are significantly lower than those for C
(p<0.02) (MDA: malondialdehyde equivalents).
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DISCUSSION

As expected, cholesterol supplementation
significantly increased plasma total cholesterol and low
density lipoprotein (LDL) levels, regardless of vitamin E
supplementation. Epidemiological studies have linked
increases of these plasma lipids with accelerated
atherogenesis and increased mortality from coronary heart
disease (Keys, 1970). Evidence also strongly supports an
important role for oxidatively modified LDL (oxLDL) in
the pathogenesis of the early atherosclerotic lesion
(Steinberg et al., 1989). It was for these reasons that
the effects of an antioxidant on plasma levels of oxLDL
as measured by thiobarbituric acid-reactive substances
was investigated. We chose vitamin E because it is the
major lipid-soluble, chain-breaking antioxidant in human
plasma (Ingold et al., 1987); it is carried in the LDL
particle (Esterbauer et al., 1992); it occurs naturally
in many foods; and, unlike synthetic antioxidants such as
probucol and butylated hydroxytoluene, it has no
contraindications or serious side effects in humans in
doses up to 1000 IU/day (Benich and Machlin, 1988).
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Our studies showed that the cholesterol diet rats
had oxidized LDL in plasma, as measured by TEARS; and
that vitamin E supplementation (300 mg a-tocopherol
acetate/kg diet) to the cholesterol diet significantly
reduced TEARS in the LDL samples by 38%. Umegaki et al.
(1991) reported that serum lipid peroxidation was reduced
in rats administered vitamin E (26 mg/rat per os) every
other day. However, that study did not isolate and
analyze LDL for oxidation. LDL oxidation has not been
found to occur in the presence of serum, and it has been
suggested that LDL is not oxidized in the circulation in
humans (Holvoet and Collen, 1994), although autoantibodies to oxLDL have been isolated from rabbit and
human sera (Palinski et al., 1989).
The level of antioxidant protection provided in this
study could possibly prevent the formation of minimally
modified LDL (mmLDL), a mildly oxidized form of LDL which
is formed by the interaction of LDL with endothelial
cells (EC), especially during transcytosis.

It is mmLDL

which initiates the formation of monocyte chemotactic
protein-1 (MCP-1) by EC (Cushing et al., 1990). MCP-1 is
the substance primarily responsible for the recruitment
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of monocytes during the early stages of atherogenesis
(Navab et al., 1991), a key step in the formation of the
early atherosclerotic lesion.
Abnormal platelet aggregation has been shown to play
a key role in the formation of the advanced atherosclerotic lesion (Ross, 1986). The release of substances
such as platelet-derived growth factor from activated
platelets plays a large role in the migration and
proliferation of smooth muscle cells from the media into
the intima (Deuel et al., 1982; Ross et al., 1974). The
resulting increase in plaque size and complexity, along
with the possible rupture of the plaque, can lead to an
infarction of tissues distal to the site of the plaque.
Thus, it would be advantageous to find a safe method
which would decrease platelet aggregation.
In rats, vitamin E has been shown to significantly
decrease platelet aggregation in response to both
collagen and adenosine diphosphate (ADP). However,
studies in humans have given mixed results, especially
for ADP. For these reasons, the effects of vitamin E
supplementation on platelet aggregation in response to
ADP and arachidonic acid (AA) were studied.
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Our studies showed that vitamin E supplementation
decreased platelet aggregation in response to both
agonists in hypercholesterolemic rats, but this decrease
did not reach statistical significance. While this is not
inconsistent with findings in humans for ADP, the great
majority of studies showed a significant decrease in

AA.-

induced platelet aggregation with vitamin E
supplementation. Our results may have been influenced by
the numbers of samples (n ranged from 5 to 8 for the
cholesterol-supplemented groups); or by plasma and/or
platelet vitamin E concentrations, a variable which was
not measured in the current study.
In conclusion, this study found that vitamin E
supplementation significantly reduced the oxidation of
LDL which occurred in hypercholesterolemic plasma, but
did not significantly reduce the platelet aggregation
responses to AA and ADP of hypercholesterolemic rats.
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